Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Status:
Not yet recruiting
Trial end date:
2023-05-20
Target enrollment:
Participant gender:
Summary
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase
IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese
patients with breakthrough cancer pain.